Pharma BD Deal Intelligence

AstraZeneca PLC / Pearl Therapeutics Inc.

2013 · Acquisition/Merger · $1.1B · Complete

Announcement Sentiment

Strongly positive

AstraZeneca to acquire Pearl for $560M upfront + up to $450M dev milestones + up to $140M sales milestones (total up to $1.15B); strengthens respiratory franchise via PT003/PT010 inhaled COPD combinations.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Jun 10, 2013
Closed Jun 27, 2013
Deal value $1.1B
Deal type Acquisition/Merger
Therapeutic area COPD (severe)
Indications COPD (severe)
Key assets PT003 (LAMA/LABA HFA MDI), PT010 (LAMA/LABA/ICS triple combo)
Mechanism Co-suspension porous-particle inhaled bronchodilators (LAMA, LABA, ICS combinations)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals